MSD’s Gardasil sales slide further due to China constraints
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus…
24 Apr 2025
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing resources to domestic operations as ongoing US tariffs risk destabilising…
24 Apr 2025
Pharma companies in Europe push for US-level drug prices
Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US, as reported by the Financial Times. Amid the threat of tariffs, pharmaceutical investments…
24 Apr 2025
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the foundation model…
24 Apr 2025
Repertoire and Genentech to develop autoimmune disease therapies
Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an autoimmune condition. In…
24 Apr 2025
Biogen’s Friedreich’s ataxia treatment authorised in UK
Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in individuals aged 16 years and…
23 Apr 2025
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight loss drug developers…